In 1977, we performed in Cagliari the first invasive prenatal diagnosis for beta-thalassemia in Europe, using fetal blood sampling by placentacentesis and chain globins analysis at 20th week of gestation. Since then we have performed more than 8,000 fetal diagnoses for beta-thalassemia using placentacentesis, fetoscopy, cordocentesis, cardiocentesis, amniocentesis, transcervical-chorionic villus sampling (TC-CVS), transabdominal (TA-CVS) and preimplantation genetic diagnosis (PGD) by embryo biopsy.
INTRODUCTION
Prenatal invasive procedures for beta-thalassemia and chromosomal defects have been reported in Tables 1 and 2 .
The most used invasive procedures in our department following nondirective genetic counseling were transabdominal chorionic villus sampling (TA-CVS), amniocentesis and fetal blood sampling (FBS) by cordocentesis and up to 2012 we have performed 56,000 prenatal diagnoses of which 8,000 for beta-thalassemia (Table 3 ) and the remaining for karyotype analysis and for other less common genetic diseases.
1,2
The most common indications were: beta-thalassemia and DNA analysis, maternal age and first trimester screening for aneuploidies and congenital infectious diseases and in several cases preimplantation genetic diagnosis (PGD).
For beta-thalassemia and other Mendelian diseases when the genetic risk was higher we used TA-CVS and polymerase chain reaction (PCR) analysis.
3
For karyotype analysis, after having considered the first trimester risk assessment by measuring the fetal nuchal translucency and biochemical test and when the cases were at higher risk, women preferred TA-CVS.
4,5 For advanced maternal age (> 35 years old) or following second trimester triple test we used TA-CVS in 35% of cases and amniocentesis in 55% of cases and in 10% we used FBS.
6
The fetal nuchal translucency (Graph 1) and nasal bone screening is performed in our center for more than 55% of the Sardinian population with 6,500 tests per year and a total of 12,000 of newborns. Such first trimester risk assessment for aneuploidies and DNA analysis for Mendelian diseases changed dramatically the indication and the subsequent opting for TA-CVS in the first trimester.
Also, women well informed following first trimester risk assessment for chromosomal abnormalities preferred TA-CVS in cases at higher risk, considering the risk for fetal loss, sampling success similar to the risk after amniocentesis and the misdiagnosis acceptable (Table 4) .
We always used freehand technique and tangential insertion to the ultrasound scanner of the spinal needle in the chorion, in amniotic cavity and in umbilical cord insertion. 7, 8 In women at age 35 years who have performed first trimester risk assessment and it resulted normal for aneuploidies, we have had in recent years a strong reduction in number of invasive prenatal procedures. [9] [10] [11] Since 2004, we also performed PGD for Mendelian diseases using embryo biopsy aspiration and multiplex PCR analysis. In Italy, the law N° 40 in 2004 stopped this procedure but in 2013 following several Court sentences we have started to perform again PGD. By applying prenatal diagnosis for Mendelian diseases such as beta-thalassemia, in Sardinia, where 11 to 13% of the local population are carrier of the disease, the number of affected newborns is reduced dramatically, as well as newborns with trisomy 21 following first trimester fetal risk assessment of aneuploidies. 
